Inhibition of alpha-glucosidase I of the glycoprotein-processing enzymes by 6-O-butanoyl castanospermine (MDL 28,574) and its consequences in human immunodeficiency virus-infected T cells.
The 6-O-butanoyl derivative of castanospermine (MDL 28,574) was previously shown to be approximately 30-fold more potent than the naturally occurring molecule at inhibiting the replication of human immunodeficiency virus (HIV) (D. L. Taylor, P. S. Sunkara, P. S. Liu, M. S. Kang, T. L. Bowlin, and A. S. Tyms, AIDS 5:693-698, 1991). We now report that consistent with its improved anti-HIV activity, MDL 28,574 is more effective (50% inhibitory concentration [IC50], 20 microM) than the parent molecule (IC50, 254 microM) at causing the accumulation of glucosylated oligosaccharides in HIV-infected cells by inhibition of glycoprotein processing. These were predominantly of the glucose 3 type, as determined by P4 Bio-Gel analysis after digestion with purified alpha-glucosidase I, indicating that, intracellularly, this enzyme is the major target for inhibition. MDL 28,574, however, was less active (IC50, 1.27 microM) than castanospermine (IC50, 0.12 microM) against the mutual target enzyme, cellular alpha-glucosidase I, in a cell-free assay system. The increased effects of MDL 28,574 against alpha-glucosidase I in cell culture were attributed to the improved cellular uptake of the more lipophilic derivative. Inhibition of this enzyme activity in HIV-infected H9 cells impaired viral glycoprotein processing and resulted in the expression of abnormally configured gp120. This did not affect virus production, but the virions had decreased infectivity which was partially related to a reduced ability to bind to CD4+ T cells.
Taylor
D L
DL
Marion Merrell Dow Research Institute Laboratories, Medical Research Council Collaborative Centre, London, United Kingdom.
Kang
M S
MS
Brennan
T M
TM
Bridges
C G
CG
Sunkara
P S
PS
Tyms
A S
AS
D000998:Antiviral Agents / Q000494:pharmacology*; D015496:CD4-Positive T-Lymphocytes / Q000821:virology; D002460:Cell Line; D006023:Glycoproteins / Q000378:metabolism*; D065089:Glycoside Hydrolase Inhibitors; D015699:HIV Envelope Protein gp120 / Q000032:analysis; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D007212:Indolizines / Q000493:pharmacokinetics / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000821:virology; D054836:Indolizidines
D000998:Antiviral Agents; D006023:Glycoproteins; D065089:Glycoside Hydrolase Inhibitors; D015699:HIV Envelope Protein gp120; D007212:Indolizines; C070715:celgosivir; D054836:Indolizidines; C037806:castanospermine